Pulmonx (NASDAQ:LUNG) Insider Geoffrey Beran Rose Sells 7,879 Shares of Stock

Key Points

• Insider sale: Geoffrey Rose sold 7,879 Pulmonx shares at an average price of $2.26, totaling $17,806.54. The filing said the sale covered tax-withholding obligations tied to vested equity awards, leaving him with 449,832 shares.
• Financial performance: Pulmonx reported a quarterly loss of $0.24 per share, better than the expected $0.28 loss, while revenue of $22.76 million exceeded estimates. Analysts project a full-year loss of $1.05 per share.
• Market outlook: LUNG traded down 0.9% to $2.26, while institutional investors owned 91.04% of the stock. Despite mixed rating changes, the shares carry a consensus “Moderate Buy” rating and a $7.67 price target.

Pulmonx Corporation (NASDAQ:LUNG - Get Free Report) insider Geoffrey Rose sold 7,879 shares of the business's stock in a transaction that occurred on Tuesday, September 1st. The stock was sold at an average price of $2.26, for a total transaction of $17,806.54. Following the sale, the insider directly owned 449,832 shares of the company's stock, valued at approximately $1,016,620.32. This trade represents a 1.72% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Pulmonx Trading Down 0.9%

LUNG stock traded down $0.02 during midday trading on Thursday, hitting $2.26. 284,129 shares of the company's stock were exchanged, compared to its average volume of 512,534. The company has a market cap of $97.07 million, a PE ratio of -1.95 and a beta of 0.34. Pulmonx Corporation has a one year low of $1.13 and a one year high of $2.89. The company has a debt-to-equity ratio of 0.95, a quick ratio of 3.52 and a current ratio of 4.32. The stock's fifty day moving average price is $1.79 and its 200-day moving average price is $1.56.

Pulmonx (NASDAQ:LUNG - Get Free Report) last issued its quarterly earnings results on Wednesday, July 29th. The company reported ($0.24) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.28) by $0.04. The firm had revenue of $22.76 million for the quarter, compared to analyst estimates of $22.39 million. Pulmonx had a negative net margin of 55.03% and a negative return on equity of 96.66%. Research analysts predict that Pulmonx Corporation will post -1.05 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Pulmonx

Several large investors have recently modified their holdings of LUNG. R Squared Ltd purchased a new position in Pulmonx in the first quarter valued at approximately $26,000. Cerity Partners LLC bought a new stake in shares of Pulmonx in the fourth quarter valued at $27,000. Opal Capital LLC purchased a new position in shares of Pulmonx during the 4th quarter valued at $29,000. Jain Global LLC bought a new position in shares of Pulmonx during the 3rd quarter worth $30,000. Finally, Sei Investments Co. bought a new position in shares of Pulmonx during the 1st quarter worth $31,000. Hedge funds and other institutional investors own 91.04% of the company's stock.

Analyst Ratings Changes

Several equities analysts have issued reports on LUNG shares. Wall Street Zen raised Pulmonx from a "sell" rating to a "hold" rating in a research note on Saturday, June 27th. Weiss Ratings raised Pulmonx from a "sell (e+)" rating to a "sell (d-)" rating in a report on Tuesday, August 25th. Three equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $7.67.

Pulmonx Company Profile

Pulmonx Corporation is a commercial-stage medical device company focused on bronchoscopic lung volume reduction for patients suffering from severe emphysema. The company's flagship therapy, the Zephyr® Endobronchial Valve System, employs one-way valves delivered via a minimally invasive bronchoscopic procedure to collapse diseased portions of the lung, reducing hyperinflation and improving respiratory function. Complementing this treatment, Pulmonx offers the Chartis® Pulmonary Assessment System, which provides clinicians with quantitative measurements of collateral ventilation to aid in patient selection and optimize clinical outcomes.

The Zephyr Valve received the CE mark in Europe in 2008 and FDA approval in the United States in 2018, and it has since been adopted by leading respiratory and thoracic centers across North America and Europe.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source